- Trials with a EudraCT protocol (59)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (1)
59 result(s) found for: Proliferative diabetic retinopathy.
Displaying page 1 of 3.
EudraCT Number: 2020-003865-20 | Sponsor Protocol Number: 21618 | Start Date*: 2021-03-02 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A clinical trial collecting Data from routine ophthalmological examinations of patients who were randomized to either finerenone or placebo in the two Bayer-sponsored Phase 3 clinical trials FIDELI... | |||||||||||||
Medical condition: Diabetic Retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003297-81 | Sponsor Protocol Number: PDRPOZU1 | Start Date*: 2011-09-12 | |||||||||||
Sponsor Name:St Eriks Eye Hospital | |||||||||||||
Full Title: A prospective, randomized study on intravitreal Ozurdex for preventing recurrent vitreous hemorrhage following pars plana vitrectomy for proliferative diabetic retinopathy | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-002333-15 | Sponsor Protocol Number: 20739 | Start Date*: 2021-01-15 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: A Phase 2 randomized, placebo-controlled, double-masked proof-of concept study to investigate the efficacy and safety of runcaciguat (BAY 1101042) in patients with moderately severe to severe non-p... | |||||||||||||
Medical condition: - Non-proliferative diabetic retinopathy: early stage of a medical condition in which damage occurs to the retina due to diabetes mellitus (DM) - DM is characterized by too much sugar in the blood | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) PL (Completed) CZ (Completed) PT (Completed) NL (Completed) DK (Completed) HU (Prematurely Ended) IT (Prematurely Ended) SK (Completed) BG (Completed) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-005032-33 | Sponsor Protocol Number: 70242 | Start Date*: 2009-01-22 | |||||||||||
Sponsor Name:Gedeon Richter Plc. | |||||||||||||
Full Title: Single center, exploratoric, double-blind, placebo controlled study to investigate the efficacy and tolerability of vinpocetine in patients with non-proliferative diabetic retinopathy | |||||||||||||
Medical condition: Patients with type 2 diabetes mellitus with mild or moderate or severe non-proliferative diabetic retinopathy (NPDR). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-001856-36 | Sponsor Protocol Number: MEDICARE | Start Date*: 2013-08-05 | |||||||||||
Sponsor Name:CHU DE POITIERS | |||||||||||||
Full Title: Efficacy and safety of Aflibercept (Eylea®) in proliferative diabetic retinopathy | |||||||||||||
Medical condition: Percentage of patients showing regression of retinal neovascularization between baseline and month 12 in the Aflibercept group versus laser group | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2009-016760-36 | Sponsor Protocol Number: CC-02-2009 | Start Date*: 2010-02-05 | |||||||||||
Sponsor Name:AIBILI | |||||||||||||
Full Title: Prospective, randomized, open label phase II study to assess efficacy and safety of Macugen® (pegaptanib 0.3 mg intravitreal injections) plus panretinal photocoagulation (PRP) and PRP (monotherapy)... | |||||||||||||
Medical condition: Proliferative Diabetic Retinopathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-024062-22 | Sponsor Protocol Number: BAIJ1006 | Start Date*: 2011-03-22 | |||||||||||
Sponsor Name:Moorfields Eye Hospital | |||||||||||||
Full Title: A prospective, randomised controlled trial of Ranibizumab pre-treatment in Diabetic Vitrectomy – a pilot study. | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-005542-35 | Sponsor Protocol Number: CRFB002DDE21 | Start Date*: 2012-05-08 | |||||||||||
Sponsor Name:Novartis Pharma GmbH | |||||||||||||
Full Title: Multicenter randomized open-label three-arms controlled 12 months clinical proof of concept study to evaluate efficacy and safety of Ranibizumab alone or in combination with laser photocoagulation ... | |||||||||||||
Medical condition: Proliferative diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-002415-15 | Sponsor Protocol Number: TG-MV-015 | Start Date*: 2016-02-17 | |||||||||||
Sponsor Name:ThromboGenics NV | |||||||||||||
Full Title: A PHASE 2, RANDOMISED, DOUBLE-MASKED, SHAM-CONTROLLED, MULTI-CENTRE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OCRIPLASMIN IN INDUCING TOTAL POSTERIOR VITREOUS DETACHMENT (PVD) IN SUBJECTS WITH N... | |||||||||||||
Medical condition: Moderately severe to very severe non-proliferative diabetic retinopathy (NPDR) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) GB (Completed) CZ (Completed) BE (Completed) HU (Completed) ES (Completed) FR (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000658-30 | Sponsor Protocol Number: prot PDR 1 | Start Date*: 2007-03-02 |
Sponsor Name:Royal Victoria Eye and Ear hospital | ||
Full Title: Randomised controlled trial of Intravitreal Bevacizumab vs. conventional treatment for proliferative diabetic retinopathy. | ||
Medical condition: Proliferative diabetic retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: IE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-014409-15 | Sponsor Protocol Number: CRFB002DPT04T | Start Date*: 2010-01-08 | |||||||||||
Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image | |||||||||||||
Full Title: Prospective, randomized, multicenter, open label phase II study to access efficacy and safety of Lucentis monotherapy (ranibizumab 0.5 mg intravitreal injections) compared with Lucentis plus panret... | |||||||||||||
Medical condition: Proliferative Diabetic Retinopathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-003640-23 | Sponsor Protocol Number: ECR-RET-2013-05 | Start Date*: 2014-01-13 | |||||||||||
Sponsor Name:AIBILI - Association for Innovation and Biomedical Research on Light and Image | |||||||||||||
Full Title: Prospective, randomized, multicentre, open label, phase II / III study to assess efficacy and safety of ranibizumab 0.5 mg intravitreal injections plus panretinal photocoagulation (PRP) versus PRP ... | |||||||||||||
Medical condition: Patients with type I or type II diabetes mellitus and high risk diabetic retinopathy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002639-14 | Sponsor Protocol Number: VGFTe-OD-1411 | Start Date*: 2016-12-29 |
Sponsor Name:Regeneron Pharmaceuticals, Inc. | ||
Full Title: A Phase 3, Double-Masked, Randomized Study of the Efficacy and Safety of Intravitreal Aflibercept Injection in Patients with Moderately Severe to Severe Nonproliferative Diabetic Retinopathy | ||
Medical condition: NonProliferative Diabetic Retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) DE (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-009909-25 | Sponsor Protocol Number: KTvsMM1/09 | Start Date*: 2009-05-05 | |||||||||||
Sponsor Name:Johann Wolfgang Goethe-Universität Frankfurt | |||||||||||||
Full Title: Evaluation of the efficacy and safety of a Macugen monotherapy versus Combined Therapies in the Treatment of Diabetic Retinopathy – a single centre, randomized, prospective Phase II trial | |||||||||||||
Medical condition: Medical condition: moderate to severe non-proliferative retinopathy with diabetic cystoid macular edema. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-004696-11 | Sponsor Protocol Number: CSMS995 0802E1 | Start Date*: 2005-06-21 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: A open-label extension study to evaluate the long-term safety and tolerability of Sandostatin LAR in the treatment of patients with moderately severe or severe non-proliferative diabetic retinopath... | ||
Medical condition: Moderately severe or severe non-proliferative diabetic retinopathy (NPDR) or low risk proliferative diabetic retinopathy | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FI (Prematurely Ended) AT (Completed) SE (Completed) DE (Completed) GB (Prematurely Ended) ES (Completed) CZ (Completed) IT (Prematurely Ended) DK (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2016-002971-91 | Sponsor Protocol Number: 1386-0012 | Start Date*: 2017-10-19 | |||||||||||
Sponsor Name:Boehringer Ingelheim Norway KS | |||||||||||||
Full Title: A randomized, double-masked, placebo-controlled exploratory study to evaluate safety, tolerability, pharmacodynamics and pharmacokinetics of orally administered BI 1467335 for 12 weeks with a 12... | |||||||||||||
Medical condition: diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Completed) GR (Completed) GB (Completed) ES (Completed) IT (Completed) PT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-006795-10 | Sponsor Protocol Number: FPH-Macugen08 | Start Date*: 2008-08-15 | |||||||||||
Sponsor Name:Frimley Park Hospital NHS Foundation Trust | |||||||||||||
Full Title: A randomised controlled trial of efficacy of Pegaptanib sodium in the prevention of proliferative diabetic retinopathy | |||||||||||||
Medical condition: Diabetic Retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2007-005601-22 | Sponsor Protocol Number: poc1doxy | Start Date*: 2008-03-27 | |||||||||||
Sponsor Name: | |||||||||||||
Full Title: Proof–of–concept study 1 (POC1): Evaluation of effect of doxycycline versus placebo on retinal function and posterior segment neovascularization in patients with severe non-proliferative or early ... | |||||||||||||
Medical condition: Diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-001351-23 | Sponsor Protocol Number: EGT022-01 | Start Date*: 2017-08-15 | |||||||||||
Sponsor Name:EyeGene, Inc | |||||||||||||
Full Title: A phase IIa, randomized, placebo-controlled, double-blind, parallel study to investigate the efficacy of EG-Mirotin subcutaneously administered in multiple doses on diabetic macular edema in diabet... | |||||||||||||
Medical condition: diabetic retinopathy patients having early diabetic macular edema (DME) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002067-10 | Sponsor Protocol Number: BP41321 | Start Date*: 2020-07-27 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A randomized, double-masked, 48-week parallel-group, placebo-controlled, proof-of-concept study to investigate the efficacy and safety of RG7774 in patients with Diabetes Mellitus Type 1 or Type 2 ... | |||||||||||||
Medical condition: Diabetic retinopathy | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SK (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
